IAP-based selective RIPK2 degrader

prolonged PD w/ 0.15 mpk SC Q3D dosing

E3 binder switch and property-based opt.

Commun. Biol., Mar. 20, 2020

GlaxoSmithKline, Stevenage, UK / PMCC


“PROTAC 6” (GlaxoSmithKline (GSK) IAP-based selective RIPK2 degrader with prolonged in vivo PD)

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: